SCHEMBL2197662

SCHEMBL2197662

Cc1nnc(NS(=O)(=O)c2ccc([N+](=O)[O-])cc2)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.68
LMNA P02545 1/20 0.68
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
HPGD P15428 2/20 0.65
PKM P14618 1/20 0.64
POLB P06746 1/20 0.58
PTPN1 P18031 1/20 0.57
AKT1 P31749 2/20 0.56
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA3 P07451 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA13 Q8N1Q1 1/20 0.51
CA14 Q9ULX7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11893082 0.83 ALDH1A1 (0.77) ALDH1A1LMNAHPGDPKMAKT1
SCHEMBL14582750 0.83 MEN1 (0.66) ALDH1A1MEN1KMT2AHPGDPKM
SCHEMBL5401322 0.82 ALDH1A1 (0.67) ALDH1A1MEN1KMT2AHPGDPOLB
Sulfamethizole SCHEMBL26453 0.81 ALDH1A1 (1.00) ALDH1A1LMNAHPGDPKMAKT1
SCHEMBL2176360 0.81 ALDH1A1 (0.73) ALDH1A1LMNAHPGDPKMAKT1
SCHEMBL1094305 0.80 ALDH1A1 (0.72) ALDH1A1LMNAMEN1KMT2AHPGD
SCHEMBL2197860 0.80 MEN1 (0.70) ALDH1A1LMNAMEN1KMT2AHPGD
Sulfamethizole SCHEMBL1566142 0.79 ALDH1A1 (0.97) ALDH1A1LMNAHPGDPKMAKT1
SCHEMBL2178229 0.79 ALDH1A1 (0.71) ALDH1A1LMNAHPGDPKMAKT1
SCHEMBL5391543 0.79 ALDH1A1 (0.72) ALDH1A1MEN1KMT2AHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 ALDH1A1 380/4885LMNA 4797/4885MEN1 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.